Matching articles for "Lipids"
Issue 137 · January 1, 2014
Drugs for Lipids

HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL…

Treat Guidel Med Lett. 2014 Jan; 12(137):1-6
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
Issue 1320 · September 7, 2009
Red Yeast Rice

Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product…

Med Lett Drugs Ther. 2009 Sep 7; 51(1320):71-2
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Issue 1317 · July 27, 2009
When a Statin Fails

The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.

Med Lett Drugs Ther. 2009 Jul 27; 51(1317):58-60
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Issue 66 · February 1, 2008
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for…

Treat Guidel Med Lett. 2008 Feb; 6(66):9-16
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.
Issue 1221 · November 7, 2005
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia

A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations…

Med Lett Drugs Ther. 2005 Nov 7; 47(1221):91-2
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription.
Issue 31 · March 1, 2005
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with…

Treat Guidel Med Lett. 2005 Mar; 3(31):15-22
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with coronary disease, some of these drugs have reduced mortality by 20% to 30%.
Issue 1196 · November 22, 2004
Safety of Aggressive Statin Therapy

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high…

Med Lett Drugs Ther. 2004 Nov 22; 46(1196):93-5
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Issue 1191 · September 13, 2004
Vytorin: A Combination of Ezetimibe and Simvastatin

Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe ( Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin ( Zocor - Merck), has been…

Med Lett Drugs Ther. 2004 Sep 13; 46(1191):73-4
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe ( Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin ( Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Issue 1186 · July 5, 2004
Amlodipine/Atorvastatin (Caduet)

Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine ( Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin ( Lipitor - Pfizer), is now available in the US. It was…

Med Lett Drugs Ther. 2004 Jul 5; 46(1186):56
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine ( Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin ( Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Issue 1176 · February 16, 2004
Drugs for Intermittent Claudication

Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608;…

Med Lett Drugs Ther. 2004 Feb 16; 46(1176):13-5
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Issue 12 · August 1, 2003
Drugs For Lipid Disorders

Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled…

Treat Guidel Med Lett. 2003 Aug; 1(12):77-82
Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled trials in patients with coronary disease, they have reduced mortality by 30% to 40%. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipid levels return to pretreatment levels in 2-3 weeks.
Issue 1115 · October 15, 2001 Free
Generic Lovastatin - Note

Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for…

Med Lett Drugs Ther. 2001 Oct 15; 43(1115):90
Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for Cerivastatin (vol. 23, page 79)